# Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®

> **NCT06319235** · PHASE1,PHASE2 · UNKNOWN · sponsor: **MB PHARMA s.r.o.** · enrollment: 52 (estimated)

## Conditions studied

- Surgical Site Infection
- Staphylococcus Aureus Infection
- Pseudomonas Aeruginosa Infection
- Bacterial Infections
- Surgical Wound Infection

## Interventions

- **DRUG:** IMP
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06319235
- **Lead sponsor:** MB PHARMA s.r.o.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-27
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2024-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06319235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06319235, "Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06319235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*